Recro Pharma Inc. (NASDAQ:REPH)’s share price shot up 13.7% during trading on Tuesday . The company traded as high as $9.93 and last traded at $9.78, with a volume of 74,729 shares traded. The stock had previously closed at $8.60.

A number of brokerages have recently commented on REPH. Zacks Investment Research downgraded Recro Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, August 18th. Brean Capital reissued a “buy” rating and set a $28.00 price objective on shares of Recro Pharma in a research report on Thursday, August 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Recro Pharma in a research report on Monday, July 18th.

The stock’s 50-day moving average price is $8.67 and its 200 day moving average price is $7.44. The firm’s market capitalization is $96.52 million.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. The company earned $17.30 million during the quarter, compared to analysts’ expectations of $18.70 million. On average, analysts anticipate that Recro Pharma Inc. will post ($3.44) EPS for the current fiscal year.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin bought 390,000 shares of Recro Pharma stock in a transaction that occurred on Tuesday, August 16th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $2,925,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.